These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32343236)

  • 21. HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
    Huhn GD; Ramgopal M; Jain MK; Hinestrosa F; Asmuth DM; Slim J; Goldstein D; Applin S; Ryu JH; Jiang S; Cox S; Das M; Nguyen-Cleary T; Piontkowsky D; Guyer B; Rossaro L; Haubrich RH
    PLoS One; 2020; 15(1):e0224875. PubMed ID: 31995556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.
    Chuang WL; Chien RN; Peng CY; Chang TT; Lo GH; Sheen IS; Wang HY; Chen JJ; Yang JC; Knox SJ; Gao B; Garrison KL; Mo H; Pang PS; Hsu YC; Hu TH; Chu CJ; Kao JH
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1323-9. PubMed ID: 26841930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
    Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C.
    Del Rio-Valencia JC; Asensi-Diez R; Tamayo-Bermejo R; Muñoz-Castillo I
    Rev Esp Quimioter; 2019 Aug; 32(4):296-302. PubMed ID: 31232572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.
    Wilson EM; Kattakuzhy S; Sidharthan S; Sims Z; Tang L; McLaughlin M; Price A; Nelson A; Silk R; Gross C; Akoth E; Mo H; Subramanian GM; Pang PS; McHutchison JG; Osinusi A; Masur H; Kohli A; Kottilil S
    Clin Infect Dis; 2016 Feb; 62(3):280-288. PubMed ID: 26521268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan.
    Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
    PLoS One; 2018; 13(12):e0209299. PubMed ID: 30576344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    Sirinawasatien A; Techasirioangkun T
    PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
    Abergel A; Metivier S; Samuel D; Jiang D; Kersey K; Pang PS; Svarovskaia E; Knox SJ; Loustaud-Ratti V; Asselah T
    Hepatology; 2016 Oct; 64(4):1049-56. PubMed ID: 27351341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N
    PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
    Thu Thuy PT; Bunchorntavakul C; Tan Dat H; Palecki J; Reddy KR
    Antivir Ther; 2018; 23(5):415-423. PubMed ID: 29303482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir.
    Younossi ZM; Stepanova M; Omata M; Mizokami M; Walters M; Hunt S
    Medicine (Baltimore); 2016 Aug; 95(33):e4243. PubMed ID: 27537553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data.
    Andres J; Lott S; Qureshi K
    J Manag Care Spec Pharm; 2018 Jan; 24(1):23-28. PubMed ID: 29290174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis.
    Stokes W; Fenton C; Clement F; James M; Ronksley P; Tang KL
    Can J Gastroenterol Hepatol; 2017; 2017():6468309. PubMed ID: 28367429
    [No Abstract]   [Full Text] [Related]  

  • 34. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
    Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.
    Wong RJ; Nguyen MT; Trinh HN; Huynh A; Ly MT; Nguyen HA; Nguyen KK; Yang J; Garcia RT; Levitt B; da Silveira E; Gish RG
    J Viral Hepat; 2017 Jan; 24(1):17-21. PubMed ID: 27677786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients.
    Marcus JL; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Lam JO; Pauly MP; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ
    Clin Gastroenterol Hepatol; 2018 Jun; 16(6):927-935. PubMed ID: 29535057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
    Flisiak R; Łucejko M; Mazur W; Janczewska E; Berak H; Tomasiewicz K; Mozer-Lisewska I; Kozielewicz D; Gietka A; Sikorska K; Wawrzynowicz-Syczewska M; Nowak K; Zarębska-Michaluk D; Musialik J; Simon K; Garlicki A; Pleśniak R; Baka-Ćwierz B; Olszok I; Augustyniak K; Stolarz W; Białkowska J; Badurek A; Piekarska A
    Adv Med Sci; 2017 Sep; 62(2):387-392. PubMed ID: 28554119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
    Lo CC; Huang CF; Cheng PN; Tseng KC; Chen CY; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Chen CH; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Chang TS; Huang JF; Yang CC; Hu JT; Lin CW; Chen CT; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Mo LR; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Liu CJ; Dai CY; Chuang WL; Lin HC; Kao JH; Yu ML;
    J Formos Med Assoc; 2022 Aug; 121(8):1567-1578. PubMed ID: 35123849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
    Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
    Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
    Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
    J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.